🇺🇸 uniQure N.V.QURE

Investor Event Form 8-K 29-09-2026 09:05:32 EDT

Subject: 8-K Items 7.01, 9.01

Overview: Announces Phase I/II study data for AMT-130 in Huntington’s disease, showing 61% slowing of TFC disease progression at 48 months in 12 high-dose patients.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest